PAVmed Inc. Schedule 13G/A reports that Tasso Partners, LLC beneficially owns 912,996 shares (14.3%) and that Dana Carrera beneficially owns 974,246 shares (15.3%). The filing ties the ownership percentages to 6,383,089 shares outstanding as of March 27, 2026 and discloses related convertible warrants and managerial control relationships.
Positive
None.
Negative
None.
Insights
Major holder structure and control links are disclosed clearly.
The filing shows that Dana Carrera controls Tasso Capital, LLC, which manages Tasso Partners, LLC, and that beneficial ownership figures combine direct trust holdings with shares held by the LLC. The ownership percentages use an explicit denominator of March 27, 2026.
Watch subsequent Section 13 filings for any material changes in shared versus sole voting or for exercises of the disclosed warrants that could affect dilution or voting thresholds.
Ownership disclosure includes complex convertible instruments and contractual limits.
The entry details 5,365 warrants exercisable into Series D Preferred Stock convertible at $6.50 per share into up to 825,385 shares, with a contractual 9.99% ownership restriction noted. The filing cites Rule 13d-3(d)(1)(i) for inclusion of certain holdings.
Compliance attention should focus on the stated ownership cap and whether future conversions or exercises will trigger amended filings.
Key Figures
Tasso Partners shares:912,996 sharesDana Carrera shares:974,246 sharesShares outstanding:6,383,089 shares+4 more
7 metrics
Tasso Partners shares912,996 sharesAmount beneficially owned by Tasso Partners, LLC
Dana Carrera shares974,246 sharesAggregate amount beneficially owned by Dana Carrera
Shares outstanding6,383,089 sharesDenominator used for percentage calculation as of March 27, 2026
Tasso Partners ownership pct14.3%Percent of class for Tasso Partners, LLC
Dana Carrera ownership pct15.3%Percent of class for Dana Carrera
Warrants disclosed5,365 warrantsWarrants exercisable for Series D Preferred Stock held by reporting person
Convertible common-equivalent825,385 sharesAggregate common shares issuable upon conversion of Series D Preferred per filing
Key Terms
Rule 13d-3(d)(1)(i), Series D Preferred Stock, contractually stipulated 9.99% ownership restriction, beneficially owned
4 terms
Rule 13d-3(d)(1)(i)regulatory
"included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act"
Series D Preferred Stockfinancial
"warrants exercisable for up to 5,365 shares of Series D Preferred Stock"
Series D preferred stock is a specific class of preferred shares typically issued in a later-stage financing round that gives holders special rights such as priority for payout before common shareholders, fixed or cumulative dividends, and often the option to convert into common shares. Investors care because these shares affect who gets paid first in a sale or liquidation, influence ownership and voting power, and change how future fundraising or an exit will impact an investor’s return—like a VIP ticket that can sometimes be exchanged for a regular ticket if that proves more valuable.
"which contain a contractually stipulated 9.99% ownership restriction"
beneficially ownedregulatory
"which are beneficially owned by Dana Carrera, which is the trustee of GCL Family Trust"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
What percentage of PAVmed (PAVM) does Tasso Partners, LLC report owning?
Tasso Partners, LLC reports beneficial ownership of 912,996 shares, equal to 14.3% of the class. The percentage is calculated using 6,383,089 shares outstanding as of March 27, 2026 as disclosed in the filing.
How many shares does Dana Carrera beneficially own in PAVmed (PAVM)?
Dana Carrera beneficially owns 974,246 shares, or 15.3% of the outstanding common stock. That total combines shares held by Tasso Partners, LLC and shares held by the GCL Family Trust, per the filing.
Are there convertible instruments disclosed in the PAVmed filing that could affect ownership?
Yes. The filing discloses 5,365 warrants exercisable into Series D Preferred Stock convertible at $6.50 per share into up to 825,385 common shares, and a contractual 9.99% ownership restriction is noted.
What denominator was used to calculate the ownership percentages in the Schedule 13G/A?
The ownership percentages were calculated using a denominator of 6,383,089 shares outstanding as of March 27, 2026, as stated in the issuer's annual report on Form 10-K filed on that date.
Who controls Tasso Partners, LLC according to the filing?
The filing states that Tasso Capital, LLC is the manager controlling Tasso Partners, LLC and that Dana Carrera controls Tasso Capital, LLC, explaining why shared powers and aggregated beneficial ownership are reported.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
PAVmed Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
70387R502
(CUSIP Number)
03/27/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
70387R502
1
Names of Reporting Persons
Tasso Partners, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
912,996.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
912,996.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
912,996.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
14.3 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: (1) Tasso Partners, LLC owns the shares of common stock of PAVmed Inc. (the "Issuer"); Tasso Capital, LLC is the manager which controls Tasso Partners, LLC and Dana Carrera controls Tasso Capital, LLC. (2) Consists of (i) 912,996 shares of common stock held by the Reporting Person and (ii) 5,365 warrants held by the Reporting Person exercisable for up to 5,365 shares of Series D Preferred Stock at an exercise price of $1,000 per share, each with a stated value of $1,000 and convertible at $6.50 per share into an aggregate of up to 825,385 shares of common stock (which the Issuer may issue directly upon exercise in lieu of the preferred shares), which contain a contractually stipulated 9.99% ownership restriction, which are beneficially owned by Dana Carrera, which is the trustee of GCL Family Trust (the "Trust"), and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended. (3) The percentage ownership was calculated based on a denominator which is the sum of 6,383,089 shares of common stock outstanding as of March 27, 2026, as set forth in the Issuer's annual report on Form 10-K filed on March 27, 2026.
SCHEDULE 13G
CUSIP Number(s):
70387R502
1
Names of Reporting Persons
Dana Carrera
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
61,250.00
6
Shared Voting Power
912,996.00
7
Sole Dispositive Power
61,250.00
8
Shared Dispositive Power
912,996.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
974,246.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
15.3 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: (1) Tasso Partners, LLC owns the shares of common stock the Issuer; Tasso Capital, LLC is the manager which controls Tasso Partners, LLC and Dana Carrera controls Tasso Capital, LLC. (2) Shared voting and dispositive power consist of (i) 912,996 shares of Common Stock held by Tasso Partners, LLC and (ii) 5,365 warrants held by Tasso Partners, LLC exercisable for up to 5,365 shares of Series D Preferred Stock at an exercise price of $1,000 per share, each with a stated value of $1,000 and convertible at $6.50 per share into an aggregate of up to 825,385 shares of common stock (which the Issuer may issue directly upon exercise in lieu of the preferred shares), which contain a contractually stipulated 9.99% ownership restriction, which are beneficially owned by Dana Carrera, which is the trustee of the Trust, and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended. (3) Sole voting and dispositive power consist of 61,250 shares of common stock owned by the Trust, which are beneficially owned by Dana Carrera, the trustee of the Trust. (4) Aggregate amount beneficially owned consists of (i) 912,996 shares of Common Stock held by Tasso Partners, LLC, and (ii) 61,250 shares of common stock owned by the Trust, which are beneficially owned by Dana Carrera, the trustee of the Trust, and included pursuant to Rule 13d-3(d)(1)(i) of the Securities Exchange Act of 1934, as amended. (5) The percentage ownership was calculated based on a denominator which is the sum of 6,383,089 shares of common stock outstanding as of March 27, 2026, as set forth in the Issuer's annual report on Form 10-K filed on March 27, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
PAVmed Inc.
(b)
Address of issuer's principal executive offices:
360 MADISON AVENUE, 360 MADISON AVENUE, NEW YORK, NEW YORK, 10017.
Item 2.
(a)
Name of person filing:
This Amendment No. 2 to Schedule 13G is filed on behalf of: (1) Tasso Partners, LLC; and (2) Dana Carrera. The foregoing persons are individually referred to as a "Reporting Person" and hereinafter collectively referred to as the "Reporting Persons". Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed as Exhibit 1 to the initial Schedule 13G filed by the Reporting Persons on February 28, 2025, pursuant to which such Reporting Persons have agreed to such Schedule 13G and all subsequent amendments to the Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act. The filing of this Amendment No. 2 Schedule 13G should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the shares of Common Stock reported herein.
(b)
Address or principal business office or, if none, residence:
The principal business address of each of the Reporting Persons is: P.O. Box 503 Rumson, NJ 07760.
(c)
Citizenship:
Tasso Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dana Carrera is a citizen of the United States.
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP No.:
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Tasso Partners, LLC - 912,996 shares of common stock
Dana Carrera - 974,246 shares of common stock
(b)
Percent of class:
Tasso Partners, LLC - 14.3%
Dana Carrera - 15.3%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Tasso Partners, LLC - 0
Dana Carrera - 61,250
(ii) Shared power to vote or to direct the vote:
Tasso Partners, LLC - 912,996
Dana Carrera - 912,996
(iii) Sole power to dispose or to direct the disposition of:
Tasso Partners, LLC - 0
Dana Carrera - 61,250
(iv) Shared power to dispose or to direct the disposition of:
Tasso Partners, LLC - 912,996
Dana Carrera - 912,996
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
Tasso Partners, LLC owns certain Issuer shares; Tasso Capital, LLC is the manager which controls Tasso Partners, LLC and Dana Carrera is the trustee of the Trust and controls Tasso Capital, LLC.
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Tasso Partners, LLC
Signature:
/s/ Dana Carrera
Name/Title:
Dana Carrera/Manager of Tasso Capital, LLC, which controls Tasso Partners, LLC
